MDGL Rockets 23% After FDA Approval for Breakthrough Liver Disease Treatment
Wasim Omar
March 15, 2024
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) encountered a tumultuous trading day on Thursday, experiencing a significant plunge from $273 to $243. However, in the afterhours, MDGL